AUTHOREA
Log in Sign Up Browse Preprints

loading page

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
  • +11
  • Naoto Saito,
  • Takeshi Hatanaka,
  • Sachi Nakano,
  • Yoichi Hazama,
  • Sachiko Yoshida,
  • Yoko Hachisu,
  • Yoshiki Tanaka,
  • Teruo Yoshinaga,
  • Kenji Kashiwabara,
  • Kubo Norio,
  • Yasuo Hosouchi,
  • Hiroki Tojima,
  • Satoru Kakizaki,
  • Toshio Uraoka
Naoto Saito
Gunma Saiseikai Maebashi Hospital

Corresponding Author:[email protected]

Author Profile
Takeshi Hatanaka
Gunma Saiseikai Maebashi Hospital
Author Profile
Sachi Nakano
Gunma Saiseikai Maebashi Hospital
Author Profile
Yoichi Hazama
Gunma Saiseikai Maebashi Hospital
Author Profile
Sachiko Yoshida
Gunma Saiseikai Maebashi Hospital
Author Profile
Yoko Hachisu
Gunma Saiseikai Maebashi Hospital
Author Profile
Yoshiki Tanaka
Gunma Saiseikai Maebashi Hospital
Author Profile
Teruo Yoshinaga
Gunma Saiseikai Maebashi Hospital
Author Profile
Kenji Kashiwabara
Gunma Saiseikai Maebashi Hospital
Author Profile
Kubo Norio
Gunma Saiseikai Maebashi Hospital
Author Profile
Yasuo Hosouchi
Gunma Saiseikai Maebashi Hospital
Author Profile
Hiroki Tojima
Gunma University Graduate School of Medicine School of Medicine Faculty of Medicine
Author Profile
Satoru Kakizaki
National Hospital Organization Takasaki General Medical Center
Author Profile
Toshio Uraoka
Gunma University Graduate School of Medicine School of Medicine Faculty of Medicine
Author Profile

Abstract

An 81-year-old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5-month progression-free survival. Atez/Bev might exhibit efficacy for CHC patients.

Peer review status:Published

31 Mar 2022Submitted to Clinical Case Reports
Show details
Hide details
01 Apr 2022Submission Checks Completed
01 Apr 2022Assigned to Editor
06 Apr 2022Reviewer(s) Assigned
19 Apr 2022Review(s) Completed, Editorial Evaluation Pending
19 Apr 2022Editorial Decision: Revise Minor
26 Apr 20221st Revision Received
27 Apr 2022Submission Checks Completed
27 Apr 2022Assigned to Editor
27 Apr 2022Review(s) Completed, Editorial Evaluation Pending
28 Apr 2022Reviewer(s) Assigned
16 Jun 2022Editorial Decision: Revise Minor
18 Jun 20222nd Revision Received
22 Jun 2022Submission Checks Completed
22 Jun 2022Assigned to Editor
22 Jun 2022Review(s) Completed, Editorial Evaluation Pending
22 Jun 2022Editorial Decision: Revise Minor
23 Jun 20223rd Revision Received
23 Jun 2022Assigned to Editor
23 Jun 2022Submission Checks Completed
23 Jun 2022Review(s) Completed, Editorial Evaluation Pending
29 Jun 2022Editorial Decision: Accept
Jul 2022Published in Clinical Case Reports volume 10 issue 7. 10.1002/ccr3.6129